Exciting time at InCephalo. Join me in welcoming Lorenz Mayr as our new Chair.
About us
InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.
- Website
-
www.incephalo.com
External link for InCephalo
- Industry
- Biotechnology
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2021
Employees at InCephalo
Updates
-
InCephalo reposted this
Calling all life sciences start-ups! 🚀 Ready to fast-track your success and navigate the regulatory landscape with confidence? Join the DIA Startup Accelerator at #DIAEurope2024 on 12 March in Brussels! This is your chance to get expert guidance directly from regulatory and HTA representatives, demystify the complex world of regulations, and unlock your full potential. Hear firsthand from start-ups like InCephalo who participated in last year's edition. Watch their inspiring journey and learn how DIA Europe helped them pave the way for success. Plus, all participating start-ups receive a complimentary full-day conference pass for DIA Europe. Ready to register? Contact Tereza.krucka@diaglobal.org today! #DIAEurope #StartUp #LifeSciences #Collaboration
-
Excited to see our CSO‘s newest paper about what happens to therapeutic antibodies once they are in the brain.
CSO, InCephalo & Groupleader, Institute of Laboratory Animal Science, University of Zurich
I am delighted to see our review on exit pathways of therapeutic antibodies from the brain and potential strategies to retain them there published in iScience. Congratulations Linda Schellhammer, PhD, Michal Beffinger, Ulisse Salazar, Jon Laman and Thorsten Buch! Did you ever wonder what happens to a therapeutic antibody once it is deployed behind the blood-brain barrier into the central nervous system compartment? Reaching the brain may not be the end of the journey. You may also want to check out InCephalo’s vision of Compartment-Locked Therapeutics. https://lnkd.in/edPynaGK
-
We wish our colleague Simon Hoehn all the best in the upcoming World Mixed Curling Championship in Aberdeen! Go Switzerland! https://lnkd.in/eedqfGsA #Curling #GoforGold #Swisscurling #CurlAberdeen #HoppSchwiiz
-
-
Exciting news - as InCephalo pushes its compartment-locked IL-12 (InC01) further. A big thank you to our collaborators VitroScan and the University of Basel for your support, and we are excited about getting the collaboration started.
InCephalo AG, University of Basel and VitroScan received a competitive Eurostars grant (€2.3M) to accelerate a novel brain cancer drug candidate.
InCephalo on LinkedIn